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ABSTRACT
Role of α6 nAChRs in Ethanol Modulation of VTA Neurons
Samuel I. Shin
Department of Physiological and Developmental Biology, BYU
Master of Science in Neuroscience
The prevailing view is that enhancement of dopamine (DA) transmission in the
mesolimbic system leads to the rewarding properties of alcohol and nicotine (NIC). The
mesolimbic DA system consists of DA neurons in the midbrain ventral tegmental area (VTA)
that innervate the nucleus accumbens (NAc). DA neurotransmission is regulated by inhibitory
VTA GABA neurons, whose excitability is a net effect of glutamate (GLU) and GABA
neurotransmission that are modulated by NIC cholinergic receptors (nAChRs) on afferent
terminals. We have previously demonstrated that VTA GABA neurons are excited by low-dose
ethanol but are inhibited by moderate to high-dose ethanol, and they adapt to chronic ethanol,
evincing marked hyperexcitability during withdrawal.
The aim of this study was to evaluate the role of α6 nAChRs in ethanol effects on VTA
GABA and DA neurons. In order to more conclusively demonstrate the role of α6 nAChRs in
alcohol modulation in the VTA, we profiled the pharmacological interactions between ethanol
and α6 nAChRs using recombinant α6 nAChRs in human epithelia (SH-EP1) cells and evaluated
the effects of α6 nAChR antagonists on ethanol inhibition of GABA-mediated synaptic
responses in dissociated GABA neurons of the VTA by recording mIPSCs; and assessed the
effects of α6 nAChR antagonists on ethanol inhibition of VTA neurons, via eIPSCs on GABA
neurons, sIPSCs on GABA neurons, and firing rate of DA neurons. We found that ethanol
enhanced NIC currents in SH-EP1 cells via α6 nAChRs. Electrophysiology studies showed that
superfusion of ethanol (5-30 mM) enhanced the frequency and amplitude of mIPSCs recorded in
acutely dissociated VTA GABA neurons from GAD-GFP mice. Furthermore, the α6 nAChR
antagonist α-conotoxin P1A (10 nM) prevented the ethanol-induced changes in mIPSC. In
support, eIPSC experiments demonstrated that low doses of ethanol (1-5 mM) enhanced eIPSC
peaks and decreased paired-pulse ratio, suggesting a presynaptic effect with ethanol. Alphaconotoxin MII (α-CTX MII) blocked ethanol’s effects on eIPSCs. This effect on VTA GABA
neurons was also seen in sIPSCs, as ethanol decreased GABA firing rate. Similarly, the
inhibition caused by ethanol was prevented by α-conotoxin P1A (10 nM). Additionally, CPP
studies showed that α6 KO mice and WT mice treated with MEC, a non-competitive, non-α7
antagonist, did not show a preference for EtOH compartments that was found in WT mice.
Taken together, these studies indicate that ethanol is acting through α6 nAChRs on
GABA terminals to enhance GABA release, suggesting a possible mechanism of action of
alcohol and nicotine co-dependence. Through these studies conducted to understand the role of
α6 nAChRs in ethanol modulation, we hope to further outline how alcohol alters brain activity so
that we can ultimately facilitate the development of therapies/medications for the treatment of
alcoholism.
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INTRODUCTION
The Economic and Social Costs of Alcohol Abuse
Alcoholism is a disorder pervasive throughout the world. Indeed, alcohol has been rated
as one of the most harmful drugs in society (Nutt, King et al. 2010). Alcoholism not only has a
negative impact on the user’s life but is also substantially detrimental to the people associated
with the user (Nutt, King et al. 2010). The consequences of such drug abuse include a decrease in
job productivity, squandered earnings, rising healthcare costs, incarcerations, investigations,
vehicular accidents, domestic and non-domestic violence, premature death, and breakdown of the
family unit (SAMHSA 2006). Alcohol abuse has huge societal and economic implications: it
afflicts at least 15.3 million individuals and the costs directly related to alcohol abuse add up to
approximately $185 billion annually in the US (Gordis 2000). Despite the negative impacts of
alcoholism, very little is understood about it neuromechanistically. Through our endeavors, we
hope to be able to understand the mechanism of how alcohol hijacks the brain in order to help
alleviate its symptoms and adverse consequences. Through improving our understanding of how
alcohol leads to addiction, dependence could be reversed through therapies and/or medication in
order to save lives.
The Mesolimbic Dopamine System
Many addictive substances are known to work through the mesolimbic dopaminergic
system (Wise and Bozarth 1987). In this system, it is believed that dopamine (DA) neurons
originating in the ventral tegmental area (VTA) of the midbrain project to the nucleus accumbens
(NAc) and the prefrontal cortex (PFC) (Wise 1996). The release of DA in the NAc is associated
with feelings of pleasure that leads to the physiological need that drives addiction (Wise 2008).
DA release in the mesolimbic DA system has been shown to have a scalar index of reward (Wise
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2008), with greater DA release being directly associated with higher feelings of pleasure. While
the release of DA in the NAc leads to symptoms of addiction, it has been suggested that the
changes in DA are mediated by VTA γ-amino butyric acid (GABA) neurons (Nugent and Kauer
2008). VTA GABA neurons provide an inhibitory input to DA neurons to regulate their activity
level (Tepper, Paladini et al. 1998). Optogenetic studies have shown that selective activation of
VTA GABA neurons influences conditioned placed aversion (Tan, Yvon et al. 2012) and can
manipulate reward consumption (van Zessen, Phillips et al. 2012). Furthermore, evidence for
GABA’s role in reward has been demonstrated by multiple labs, including our own, as
substances such as nicotine (NIC)
and alcohol can alter GABA activity
(Yin and French 2000, Erhardt,
Schwieler et al. 2002, Mansvelder,
Keath et al. 2002) to influence DA
activity (Brodie and Appel 1998).
This suggests that GABA is a major
regulator of DA neurotransmission
and therefore plays a critical role in
the rewarding properties of drugs
such as ethanol (EtOH) and NIC.
Figure 1 portrays the synaptic
hodology of VTA GABA neurons,
including probable receptors involved
in EtOH and NIC mechanisms.

Figure 1: Theoretical Framework for Proposed Studies.
Dopamine neurons in the VTA project to the NAc via the
medial forebrain bundle (MFB). Interestingly, although
considerable attention has been placed on the role of the DA
projection from the VTA to the NAc in drug reward and
abuse, VTA GABA neurons also project to the NAc (Carr
and Sesack 2000). Moreover, a subset of GABAergic NAc
neurons sends a reciprocal projection back to the VTA
(Tripathi, Prensa et al. 2010). This reciprocal loop between
GABA neurons in the VTA and GABA neurons in the NAc
is believed to provide inhibitory feedback to regulate DA
neuron activity (Rahman and McBride 2000) via VTA
GABA neurons (Xia, Driscoll et al. 2011). They may also
be inhibited by local circuit GABA neurons and
GABAergic input from the RMTg. Cholinergic (ACh) input
from the PPTg excites GABA and DA neurons via α4β2
nAChR.
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Ethanol-Nicotine Interactions
Alcohol and tobacco are some of the most prevalent drugs in society and often are coabused. Because of this observation, many have suspected that alcohol and NIC (the addictive
component of tobacco) may have some form of synergistic interaction. This hypothesis is
promoted, as studies have shown that the amount of NIC intake through tobacco is positively
correlated with the amount of alcohol consumed and the degree of alcohol dependence (John,
Meyer et al. 2003). Additionally, studies measuring NIC and EtOH at the level of discriminative
stimulus effects found that smoking promotes greater alcohol consumption (Ford, McCracken et
al. 2012). Systemic co-administration of low doses of alcohol and NIC in the VTA also resulted
in an additive effect on DA release (Tizabi, Copeland et al. 2002). These findings are further
substantiated as alcohol consumption increased pleasure and desire for smoking (Harrison,
Hinson et al. 2009). This cumulated evidence suggests that NIC and EtOH could have a shared
mechanism that explains how one drug may influence the other and facilitate addiction. The data
shows behavioral and cellular support for the interactive properties between alcohol and NIC and
advocates the need for further research to understand the possibly shared circuitry.
While alcohol’s effects are often misunderstood and can be controversial, NIC’s method
of action has been outlined more clearly and definitively. NIC addiction has been known to be
mediated by nicotinic acetylcholine receptor (nAChR) desensitization of neurons from the VTA
projecting to limbic structures (Mansvelder and McGehee 2000, Mansvelder, Keath et al. 2002).
Neurons within the VTA express a wide variety of nAChRs (Wooltorton, Pidoplichko et al.
2003), and NIC can activate both DA and GABA neurons (Yin and French 2000, Mansvelder,
Keath et al. 2002), with the majority of endogenous cholinergic inputs contacting GABA in the
VTA (Garzon, Vaughan et al. 1999, Fiorillo and Williams 2000).
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The majority of the GABA neurons in the VTA express α4 and β2 nAChR subunits,
which can be blocked by the non-competitive, non-α7 antagonist mecamylamine (MEC) or by
the competitive antagonist dihydro-β-erythroidine hydrobromide (DHβE) (Mansvelder, Keath et
al. 2002). In addition to the transient actions of NIC on DA and GABA neurons via α4β2
nAChRs, considerable evidence indicates that the actions of NIC within the VTA may be
mediated by glutamatergic (GLUergic) transmission. Blockade of GLU NMDA receptors
(NMDARs) and α7-nAChRs in the VTA reduces the spike in DA release that is normally
induced by NIC (Schilstrom, Svensson et al. 1998, Schilstrom, Fagerquist et al. 2000), and
systemically- or locally-injected NMDA antagonists into the VTA can block the rewarding
effects of NIC (Papp, Gruca et al. 2002, Laviolette and van der Kooy 2003). The VTA receives
GLUergic input from the PFC, providing the major excitatory control of the VTA, influencing
DA release in the NAc (Johnson, Seutin et al. 1992, Sesack and Pickel 1992, Suaud-Chagny,
Chergui et al. 1992, Kalivas, Churchill et al. 1993, Taber and Fibiger 1995).
NIC receptors on GLUergic terminals in the VTA are located presynaptically.
Specifically, these receptors are homomeric α7-nAChRs (Mansvelder and McGehee 2000),
which enhance the release of GLU on DA and GABA neurons (McGehee, Heath et al. 1995,
Girod, Barazangi et al. 2000). They are sensitive to the α7-nAChR antagonist methylylcaconitine
(MLA). It has been proposed that the general mechanism of NIC addiction is that all nAChRs
become desensitized by NIC (Mansvelder, Keath et al. 2002). NIC is present in the brain of
smokers about 10-20 sec after absorption (Oldendorf 1974, Benowitz 1988), reaching blood
concentrations of NIC in the range of 250 and 500 nM during and after cigarette smoking
(Henningfield, Stapleton et al. 1993). We have recently shown that NIC activates GABA neurons
in the VTA via α7 nAChRs on GLU terminals (Taylor, Burman et al. 2013) , probably arising
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from the PFC. However, α7-nAChRs take a higher dose in order for desensitization to occur and
recover in the order minutes (Fenster, Rains et al. 1997), as opposed to hours for all other
nAChRs. It has been proposed that a shift occurs in the activity level of DA neurons relative to
GABA cells in the VTA after prolonged exposure to NIC, and this shift would favor increased
activity of the mesolimbic DA pathway and DA release in the NAc (Mansvelder, Keath et al.
2002).
In addition to α4β2 and homomeric α7-nAChRs, there is a considerable concentration of
heteromeric α6-containing nAChRs (α6*-nAChRs; * denotes α6 subunits combined with other
nAChR subunits) in the VTA. Alpha6*-nAChR subunits are functional in recombinant systems
when paired with β subunits or hybrids of β subunits. In fact, nAChR α6 subunit mRNA level is
16-fold higher than other subunits in the VTA (Yang, Hu et al. 2009). They have been implicated
in DA transmission and NIC dependence (Drenan, Grady et al. 2008, Exley, Clements et al.
2008, Jackson, McIntosh et al. 2009, Drenan, Grady et al. 2010, Gotti, Guiducci et al. 2010).
EtOH is unlikely to have a direct effect on nAChRs. Instead, these changes caused by
EtOH could be mediated by plasticity involving other mechanisms. For example, plasticity in
GABAergic synapses of the VTA has been discovered with several addictive substances (Nugent
and Kauer 2008). To induce LTD and/or LTP, EtOH could activate GABA receptors directly or
act on the GLUergic synapses, which promote endocannabinoid-mediated LTD of GABA
neurons, as has been observed with other substances (Nugent and Kauer 2008). Additionally,
other processes could involve alcohol increasing ACh release in the VTA to potentiate nAChRs
(Larsson, Edstrom et al. 2005). These potential pathways exhibit a likelihood of alcohol acting
on nAChRs that encourages further examination to explain how alcohol leads to addiction and its
interaction with NIC.
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RATIONALE AND HYPOTHESES
As discussed, GABAergic synaptic transmission is still regarded as one of the main
factors underlying the intoxicating, rewarding, and withdrawal-related effects of EtOH (Bonci
and Williams 1996, Bonci and Williams 1997). The emerging view is that DA neurons in the
VTA are under strong, tonic inhibition by GABA innervations. Interestingly, it has been
demonstrated by others that the inhibitory drive to GABA neurons exceeds that of DA neurons
(Tan, Brown et al. 2010). Consistent with what has been reported, we have found that VTA
GABA neurons in horizontal slice preparation have higher spontaneous inhibitory postsynaptic
current (IPSC) rates than DA neurons (GABA neurons: 10.4 ± 1.3 Hz; DA neurons: 5.4 ± 0.6
Hz; n=24,16; (Allison, Wilcox et al. 2011)). The inhibitory drive to VTA GABA neurons could
be mediated by other local circuit GABA neurons or by GABA inputs from the ventral pallidum,
NAc, or RMTg. Spontaneous IPSC (sIPSC) rate in VTA GABA neurons in coronal slices (5.2 ±
0.3 Hz; n=15) is approximately 50% that of horizontal slices. Horizontal slices contain the
RMTg, suggesting that the RMTg might be providing this strong inhibitory input to VTA GABA
neurons, as GABA input from the NAc is unlikely to have any influence in horizontal slices.
Inhibition of VTA GABA neurons is mediated by α1 subunit-containing GABA(A)Rs that are
selectively expressed in GABA neurons, but not in DA neurons, in the VTA (Okada, Matsushita
et al. 2004, Tan, Brown et al. 2010). Most interestingly, GABA neurons, recorded both in vivo
and ex vivo, have high spike activity even in the presence of pronounced afferent GABAergic
drive.
The effects of EtOH on GABA(A)R-mediated inhibition on VTA DA neurons are
controversial. For example, one lab has reported that EtOH (20-50 mM) enhances sIPSC
frequency on DA neurons (Theile, Morikawa et al. 2008), while another has reported that EtOH
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(10-40 mM) reduces sIPSC frequency on DA neurons (Xiao and Ye 2008). We are possibly the
only lab that has looked at the effects of EtOH on the pronounced GABA input to
unambiguously characterized VTA GABA neurons. Although we have studied scores of cells at
5-60 mM EtOH, we have not seen consistent effects of EtOH on VTA GABA neuron sIPSCs in
the slice preparation in the presence of GLU blockers APV and CNQX. However, we aim to
show consistent and reproducible preliminary evidence that low doses of EtOH enhance
miniIPSC (mIPSCs) in dissociated VTA GABA neurons, which is blocked by α6*-nAChR
antagonists.
While α6*-nAChRs have relatively limited expression in the brain, they are markedly
expressed in the VTA, as discussed earlier. They are also expressed in the striatum and their
activation modulates DA release (Grady, Salminen et al. 2007). Blocking α6*-nAChRs has been
shown to modulate EtOH-induced enhancement of DA release as measured by microdialysis
(Larsson, Jerlhag et al. 2004). Despite the fact that mice lacking the α6 subunit did not differ in
EtOH consumption or EtOH-induced ataxia, they did exhibit more EtOH-induced sedation
(Kamens, Hoft et al. 2012). Thus, modulation of GABA inhibition of GABA neurons by α6*nAChRs may be an important regulator of GABA neuron excitability, which ultimately will
govern DA neurotransmission.
Thus, our goal is to define the role of α6*-nAChRs in acute EtOH actions. Our objectives
were three-fold: 1) To define the role of α6*-nAChRs in acute EtOH actions on VTA neurons; 2)
To outline the role of α6*-nAChRs in acute EtOH actions on DA activity and release; and 3) To
identify the role of α6*-nAChRs in mediating EtOH consumption and reward. Through using
experimental procedures to address these aims, we expected to help implicate the role α6*nAChRs in mediating the effects of alcohol and NIC and co-dependence on these substances.

7

METHODS
Animal Subjects
Black wild-type (WT) male C57BL/6 mice, α6 KO mice, and glutamate-decarboxylase67 (GAD-67)-green fluorescent protein knock-in (CD-1) mice (Tamamaki, Yanagawa et al.
2003) were bred and cared for in accordance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals. For each methodology to be employed, animals were
treated in strict accordance with the Brigham Young University Animal Research Committee
(IACUC) guidelines, which incorporate and exceed current NIH guidelines. The BYU IACUC
has reviewed and approved the procedures detailed herein. Once weaned at PND 21, all mice
were housed in maximum groups of four and given ad libitum access to solid food and water and
placed on a reverse light/dark cycle with lights ON from 8 p.m. to 8 a.m.
Preparation of Brain Slices
All brain slice preparations were performed in P18-45 day old C57BL/6 and GAD-GFP
knock-in mice. Brains were extracted via under isoflurane (5%) anesthesia and by intraperitoneal
(IP) injection with ketamine (60 mg/kg). Upon extraction, the brain was glued onto a cutting
stage. The brain was sectioned in ice-cold cutting solution (in mM: 220 Sucrose, 3 KCl,
1.25 NaH2PO4, 25 NaH2CO3, 12 MgSO4, 10 Glucose, 0.2 CaCl2, and 0.4 Ketamine) and was
perfused with 95% O2 / 5% CO2. Horizontal slices (targeting the VTA were 210 μM thick;
targeting the NAc were 400 μM thick) were placed in an incubation chamber containing artificial
cerebral spinal fluid (ACSF; in mM: 124 NaCl, 3 KCl, 1.25 NaH2PO4, 26 NaHCO3, 12 glucose,
1.5 MgSO4, 2 CaCl2) perfused with 95% O2 / 5% CO2 for at least 30 min. After 30 min, brain
slices were placed in a recording tissue chamber with ACSF continuously flowing at
physiological temperature (36 °C).
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Characterization of Neuron Types
GABA neurons were studied in GAD-GFP knock-in mice and C57BL/6 mice. In GADGFP knock-in mice, VTA GABA neurons were identified by a characteristic glow under
fluorescence illumination. In C57BL/6 mice, VTA GABA neurons were characterized using a
GABA spike command waveform [spikes at 200 Hz for 500msec; (Steffensen, Taylor et al.
2008)] as GABA neurons will follow the command waveform. Neurons that did not fluoresce
and/or exhibit a non-cation specific inward rectifying current (Ih) with low input resistance, not
following the waveform are assumed to be DA neurons (Johnson and North 1992, Allison, Ohran
et al. 2006, Margolis, Lock et al. 2006, Allison, Wilcox et al. 2011, Steffensen, Bradley et al.
2011).
Whole-Cell Recordings In Vitro
Electrodes were pulled from borosilicate glass capillary tubes (1.5 mm o.d.; A-M
Systems, Sequim, WA) and filled with a KCl pipette solutions [in mM: 128 KCl, 20 NaCl,
0.3 CaCl2, 1.2 MgCl2, 10 HEPES, 1 EGTA, 2 Mg-ATP, and 0.25 Na-GTP (pH 7.3)] for eIPSC
studies. Pipettes having tip resistances of 2.5 – 5 MΩ, and series resistances typically ranging
from 7 to 15 MΩ were used. Voltage clamp recordings were filtered at 2 kHz while current-drive
spikes were filtered at 10 kHz with an Axon Instruments Multiclamp 700B amplifier and
digitized at 5 to 20 kHz respectively using an Axon 1440A digitizer. Axon Instruments pClamp
ver10, Mini Analysis (Synaptsoft: Decatur, GA), and Igor Pro (Wavemetrics: Oswego, OR)
software packages were utilized for data collection and analysis. eIPSCs were recorded in the
presence of 50 μM APV and 30 μM CNQX or 3 mM kynurenic acid to block NMDA and
AMPA mediated synaptic currents. Using a paired-pulse stimulus, the stimulation was adjusted
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to a half-max level in order to allow measurements of changes that increase or decrease eIPSC
levels.
Cell-Attached, Voltage-Clamp Recording of Spike Activity in Brain Slices
Electrodes used for cell-attached, voltage-clamp spike studies of DA neurons were pulled
from borosilicate glass capillaries (1.5 mm o.d.; A-M Systems, Sequim, WA) and then filled
with 150 mM NaCl (2.5-5 MΩ). Positive pressure was applied to the electrode when
approaching the neuron under visual inspection. The electrode was pushed against the cell
membrane and suction was applied to create a seal (10 MΩ – 1 GΩ) between the cell membrane
and the recording pipette. Spontaneous spike activity was then recorded in voltage-clamp mode
with an Axon Instruments Multiclamp 700B amplifier and sampled at 10 kHz using an Axon
1440A digitizer, and collected and analyzed using pClamp10 software. Neurons were voltageclamped at 0 mV throughout the experiment. A stable baseline recording of firing activity was
obtained for 5-10 min before adding any substances.
Carbon Fiber Electrodes, Calibration, and Fast Scan Cyclic Voltammetry
For ex vivo voltammetry recordings a 7.0 µm diameter carbon fiber was inserted into
borosilicate capillary tubing (1.2 mm o.d.; A-M Systems, Sequim, WA) under negative pressure
and subsequently pulled on a vertical pipette puller (Narishige, East Meadow, NY). The carbon
fiber electrode (CFE) was then cut under microscopic control with 150 µm of bare fiber
protruding from the end of the glass micropipette. We then filled the CFE with 3M KCl. The
CFEs were calibrated with a known concentration of DA. With the CFE immersed in the solution
of ACSF, we perfused a known concentration of DA past the electrode and observed the
maximum nA signal produced by DA. All of these calibrations were averaged and gave us a
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calibration factor that allowed us to convert a nA signal of DA to µM concentration of DA.
Previous studies have revealed that DA current is linearly proportional to DA concentration.
For ex vivo voltammetry recordings, electrodes were positioned ~75 µm below the
surface of the slice in the NAc core. Dopamine release was evoked every 2 min by a 1 msec, one
to ten-pulse stimulation (biphasic, 350 µA) from a bipolar stimulating electrode (Plastics One,
Roanoke, VA) placed 100-200 µm from the CFE. The electrode potential was linearly scanned
as a triangular waveform from -0.4 to 1.2 V and back to -0.4 V vs Ag/AgCl using a scan rate of
400 V/s. Cyclic voltammograms were recorded at the carbon fiber electrode every 100 msec (i.e.
10 Hz) by means of a voltage clamp amplifier (ChemClamp, Dagan Corporation, Minneapolis,
MN). Voltammetric recordings were performed and analyzed using LabVIEW (National
Instruments, Austin, TX)-based customized software (Demon Voltammetry, (Yorgason, Espana
et al. 2011)). Stimulations were performed periodically every 2 min. Dopamine levels were
monitored for a stabilization period typically lasting 1 hr. Once the stimulated DA response was
stable for five successive collections, and did not vary by more than 5%, baseline measurements
were taken.
Conditioned Place Preference
The conditioned place preference (CPP) apparatus (Med Associates, St. Albans, VT)
consisted of two adjacent conditioning compartments (20 x 16 x 21 cm) separated by a manual
guillotine-type door. One of the compartments was equipped with vertical striped acrylic walls
and a steel mesh floor; the other was equipped with plain acrylic walls and a wire rod floor.
Infrared photobeams monitored the animal’s position in the apparatus and provided a measure of
motor activity. First animals were habituated to the testing apparatus during a single 20 min
session with free access to both conditioning compartments. Animals were then subjected to two
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20 min pre-conditioning tests in order to determine any initial preference for one of the
conditioning compartments. Each animal was then assigned to EtOH (2 g/kg IP) in the initially
non-preferred compartment, and saline in the initially preferred compartment. Next, the animals
underwent 20 min conditioning sessions twice daily. Saline conditioning sessions were
conducted in the morning and EtOH conditioning sessions were conducted in the afternoon.
Following 4 sequential conditioning days, animals were tested for place preference by allowing
free access to both conditioning compartments for 20 min.
Drug Preparation and Administration
Methylylcaconitine (10 nM) was prepared fresh in distilled water. CNQX (30 μM;
Abcam) and APV (50 μM; Abcam) were dissolved in distilled water and frozen until used.
Kynurenic acid (3 mM; Sigma-Aldrich) was made fresh in distilled water and sonicated to get
into solution. α-conotoxin MII (100 nM; provided by Michael McIntosh from the University of
Utah) was prepared fresh by dissolving in distilled water. Atropine (10 μM; Sigma-Aldrich) and
eticlopride (100 nM; Sigma-Aldrich) were dissolved in distilled water, while CGP55845 (10
μM;Abcam) required sonication to completely dissolve.
While measuring eIPSCs, kynurenic acid or the combination of APV and CNQX was
added to the ACSF perfused to the brain slice to block currents from AMPA and NMDA.
Afterwards, an EtOH dose response (1 mM, 5 mM, 10 mM, 30 mM, and 50 mM; approximately
5 min at each dose) was administered to the ACSF to observe its effect on eIPSCs. In some
experiments, only one dose of EtOH per slice was administered. In other experiments,
CGP55845, atropine, and eticlopride was added to kynurenic acid/APV+CNQX to rule out
GABA(B)R, D2R, and cholinergic muscarinic effects. After ensuring that EtOH had altered
eIPSC peaks, the α6 nAChR antagonist, α-contoxin MII, was added before the EtOH dose
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response in order to see if it blocked EtOH’s effects. In FSCV studies measuring DA release,
methylylcaconitine (MLA), a α7-nAChR antagonist, was perfused to the brain slice preceding
exposure to EtOH.
CPP studies were administered a dose of mecamylamine (2 mg/kg), a non-α7 nAChR
antagonist. MEC was used in vivo to block nAChR, including α6*, as conotoxins (P1A and MII)
are impermeable to the blood brain barrier.
Statistical Analyses
All results were presented as raw mean values and percent control ± SEM. Results
between groups were compared using a two-tailed unpaired t test or ANOVA. Experiments
relying on variance in time or current were analyzed using mixed models ANOVA with post hoc
t-test at individual points. Statistical significance required ≥ 95% level of confidence (P≤0.05).
CPP experiments used a post-hoc Bonferronni Multiple Comparison Test to compare the three
groups. Analysis software included Microsoft Excel and Igor Pro (Wavemetrics, Oswego, OR).
Significance levels were indicated on graphs with asterisks *,**,*** and correspond to
significance levels P<0.05, 0.01 and 0.001, respectively. Figures were constructed with Igor Pro
software.
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RESULTS
The Role of α6*-nAChRs in Acute Ethanol Actions on VTA GABA Neurons
Interactions Between Acute EtOH and α6*-nAChRs: Recombinant Studies
Our first goal was to profile pharmacological features of interaction between EtOH and
α6*-nAChRs. To accomplish this, we evaluated EtOH effects on the function of heterologously
expressed α6*-nAChR-mediated currents in recombinant α6*-nAChRs expressed in an human
epithelia (SH-EP1) cell line. Although not as physiologically relevant as native systems,
recombinant expression systems have several advantages including: 1) Better control over which
subunits are being expressed (e.g., showing the difference between different combinations of
subunits); 2) Better access to the cell in order to perform more accurate dose-response curves
(e.g., less concern about the concentration of the drug becoming diluted as it diffuses into the
tissue, etc.); 3) Better kinetic profiling of the responses (i.e., rise times, decay times, total
current, peak amplitudes, desensitization rates); 4) Less artifact than with slices; 5) Simplified
pharmacological analysis of the currents; and 6) Facilitation of the study of human nAChR
subunits in an expression system. Furthermore, this expression system is extremely valuable as
there are currently no available α6*-nAChRs agonists or direct α6*-nAChR-mediated effects in
native neurons. Hence, incorporating this expression system was essential for a full
understanding of EtOH effects on NIC currents.
Others have shown functional α6*-nAChRs using combinations of α6, α4, and β3
subunits. Therefore, we hypothesized that a combination would yield functional receptors to
study EtOH effects on NIC currents. However, NIC currents are small, and interpretations
regarding EtOH effects on α6 are put in question because of the addition of α4. Consequently,
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we established a functional cell line (SH-EP1) that stably expressed functional α6*-nAChRs
including human α6, β4 and mutated β3 (β3V9’V).
We evaluated the subunit profile necessary to optimize NIC currents and constructed
dose-response curves for NIC alone and after EtOH superfusion. NIC was able to induce a
typical dose response in NIC currents, indicating that the α6*-nAChRs in SH-EP1 cells were
functional (Fig. 2A) and sensitive to the highly selective and potent α6*-nAChR antagonist, αconotoxin P1A (α-CTX P1A) at a concentration of 1 nM (Fig. 2B). Through confirming that the
α6*-nAChRs were appropriately responsive, we were able to test the effects of EtOH on these
channels. We found that EtOH, at very low concentrations (1 mM) enhanced NIC currents in
SH-EPI cells (Fig. 2C, D), suggesting a potent and direct effect on α6*-nAChRs.

Figure 2: EtOH Enhances NIC Currents in SH-EP1 Cells Expressing α6*-nAChRs.
(A) NIC dose-response curve showed the functional a6*-nAChRs. Inset: Representative typical inward
current responses induced by difference concentrations of NIC. (B) NIC-induced current was sensitive to
very low concentration (1 nM) of selective a6-nAChR antagonist, a-Ctx P1A. (C) NIC-induced current
was reversibly enhanced by co-application of NIC and EtOH (1 mM). (D) Bar graph summarizes a group
of cells tested (indicated by number in each column) in C.
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Acute EtOH’s Effect on VTA GABA Neurons via α6*-nAChRs: Dissociated Studies
To increase our understanding of α6*-nAChRs involvement in alcohol addiction, we
proposed to evaluate the effects of α6*-nAChR antagonists on EtOH effects on GABA-mediated
synaptic responses in dissociated GABA neurons of the VTA. We set to determine this through
studying GABA-mediated mIPSCs in dissociated, visually-identified VTA GABA neurons from
GAD-GFP mice with fluorescent optics. Recently, it has been shown that dissociated DA
neurons in the VTA have inhibitory synaptic boutons that contain α6*-nAChRs, and that ACh
activation of these receptors leads to enhancement of inhibitory transmission (i.e., mIPSCs) that
are GABA(A)R mediated (Yang, Buhlman et al.). The effects of nAChR antagonists on EtOH
effects on mIPSCs, but not mEPSCs, can be studied in dissociated neurons.
Although dissociated neuron recordings suffer from the lack of physiological relevancy
characteristic of intact circuits in the slice preparation or in vivo, its value in our proposed studies
was three-fold: 1) Using the U-tube method, EtOH and NIC pharmacology can be accurately and
easily studied; 2) While there are viable inhibitory somatic synaptic boutons on dissociated
neurons, there are little or no dendritic excitatory synaptic boutons; and 3) Postsynaptic effects
can be easily assessed with pharmacological blockers. For example, CGP55845 and atropine was
included in the superfusate to assure GABA(A)R-mediated responses. To further confirm this we
also superfused the GABA(A)R antagonist bicuculline (10 mM) at the end of some experiments
to confirm that the mIPSCs were mediated by GABA.

16

In our studies, similar to what has been reported previously in dissociated DA neurons
(Yang, Buhlman et al. 2011), VTA GABA neurons evinced mIPSCs, which were enhanced by
NIC (Fig. 3A). This enhancement could then be prevented by α-conotoxins (Fig. 3B).

Figure 3: NIC Enhances mIPSCs in VTA GABA Neurons Through α6*-nAChRs.
Bath-application of nicotine (1 mM) significantly increased mIPSC frequency (A), and this effect was prevented
by pretreatment with the α6*-nAChR antagonist, α-conotoxin P1A (10 nM, B). (C) Bar graph summarizes the
pool data and suggests that nicotine activates α6*-nAChRs on GABAergic presynaptic boutons and increases
presynaptic GABA release.
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Expounding upon our results from our recombinant system experiments, we found that
EtOH enhanced both the frequency and amplitude of GABA mIPSCs at low doses, similar to
NIC effects (Fig. 4). This is a critical finding, as it supports the literature demonstrating that
EtOH enhances GABA release at physiologically relevant concentrations.

Figure 4: EtOH Enhances mIPSC Frequency and Amplitude in VTA GABA Neurons.
(A) Images show an acutely-dissociated VTA neuron from a GAD-GFP mouse using phase-contrast (Aa) and
GPF-filtered (Ab) modes of microscope. (B) A typical trace shows the spontaneous mIPSCs (in the presence of
0.5 µM TTX) since they are sensitive to a selective GABA(A)R blocker, bicuculline. (C) Bath exposure of 6
mM EtOH increased the frequency of spontaneous mIPSCs. Further analysis shows that 6 mM EtOH increases
frequency (D) and amplitude (E) of the spontaneous mIPSCs. (F) Bar graphs summarize the effects of EtOH.
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Of particular relevance to NIC and EtOH interactions, we found that the α6*-nAChR
antagonist α-ctx P1A also blocked EtOH’s enhancement of mIPSCs amplitude and frequency
(Fig. 5A, B), suggesting that α6*-nAChRs on GABA terminals to VTA GABA neurons are an
important link for EtOH and NIC interactions. Moreover, the enhancement of mIPSCs by EtOH
in WT mice was not observed in α6 KO mice (Fig. 5C, D), providing further evidence that EtOH
acts via presynaptic α6*-nAChRs to increase GABA release. These findings suggest that EtOH
is enhancing GABA release at terminals and GABA responses postsynaptically.

Figure 5: EtOH Enhancement of GABA mIPSCs to VTA GABA Neurons via α6*-nAChRs.
Results here are shown at the 30 mM EtOH level. (A) EtOH dose response on mIPSC frequency. (B) EtOH
dose response on mIPSC amplitude. (C) The α-conotoxin P1A (10 nM) did not affect mIPSC frequency, but
following a 2 min treatment, it prevented EtOH (30 mM)-induced increase in mIPSC frequency in WT mice
but not in α6 KO mice. (D) Similarly, P1A did not affect mIPSC frequency, but following a 2 min treatment,
it prevented EtOH (30 mM)-induced increase in mIPSC frequency in WT mice but not in α6 KO mice
Vertical bars represent means ± SEM.
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In further support of a postsynaptic effect, we performed GABA current experiments to
study EtOH’s influence on GABA. In dissociated VTA GABA neurons from GAD-GFP mice we
found that EtOH augmented GABA currents in VTA GABA neurons (Fig. 6).

Figure 6: Effects of EtOH on Synaptic GABA Responses in VTA GABA Neurons.
Simultaneous recordings of mIPSCs and GABA-induced whole-cell (WC) currents were made in
VTA GABA neurons (A). 6 mM EtOH and 3 mM GABA were repetitively co-applied (1 sec
exposure) to a dissociated VTA GABA neuron, which showed an enhancement in mIPSC frequency
(arrows) and amplitude and WC current amplitude (B).

Next, we wanted to confirm that
increased inhibitory input to GABA neurons
would result in an inhibition of their firing
rate. To accomplish this we decided to
measure the effects of EtOH on firing rate in
dissociated VTA GABA neurons. Using cellFigure 7: α-Ctx PIA Blocks the EtOH Effect on
VTA GABA Neurons.
In dissociated VTA GABA neurons from a GADGFP mouse, EtOH (30 mM) significantly decreased
firing rate. This decrease in firing rate was blocked
by the α6-nAChR antagonist, α-Ctx PIA (10 nM).

attached, voltage-gated patch clamp studies,
we were able to measure the firing rate of
these GABA neurons. In our results, we found

that EtOH (30 mM) caused a significant decrease in GABA firing rate (Fig. 7). Furthermore, this
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decrease in firing rate was prevented by the α6 nAChR antagonist, α-CTX P1A (10 nM; Fig. 7).
These results provide further support to our hypothesis that EtOH is enhancing GABA inhibition
to VTA GABA neurons EtOH and the role of α6*-nAChR in this process.
Acute EtOH’s Effect on VTA GABA Neurons via α6*-nAChRs: Slice Studies
Next, for more physiological relevancy we evaluated the effects of EtOH in the slice
preparation. In our slice studies, we utilized GAD-GFP mice to unequivocally identify VTA
GABA neurons, similar to the dissociated neuron studies. Additionally, some studies were also
performed in C57BL/6 mice, in case of possible EtOH sensitivity differences between the
species. For example, GAD-GFP mice only express 50% of the GAD levels of WT mice. For
these mice, we employed a variation of the conventional criteria to classify GABA neurons in
C57BL/6 mice. Mainly, GABA neurons were subjected to our GABA spike command waveform
[spikes at 200 Hz for 500 msec; (Steffensen, Taylor et al. 2008)]. We have found that GABA
neurons follow the command waveform while DA neurons do not. Additionally, GABA neuron
spike activity is enhanced or not affected by DA (Stobbs, Ohran et al. 2004, Lassen, Brown et al.
2007) while DA neurons are well-known to be inhibited by DA or D2 agonists.
In order to test EtOH’s effects on GABA-mediated responses and the role of α6*-nAChR,
we performed synaptic evoked IPSC (eIPSC) studies. For these synaptic studies involving
GABA(A)R responses, we included APV and CNQX to block excitatory synaptic transmission.
In some experiments, we also included 10 mM CGP55845 to rule out GABA(B)R effects, 100
nM eticlopride to rule out D2R effects, and 10 mM atropine to rule out cholinergic muscarinic
effects. This served as essential control conditions for nAChR studies in the slice. Notably, a
recent study had shown interactions with EtOH and CNQX (Brickley, Farrant et al. 2001,
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Maccaferri and Dingledine 2002). Thus, in some studies we used kynurenic acid (3 mM) to block
GLU transmission in place of APV and CNQX.
While mIPSCs are best evaluated in dissociated neurons, eIPSCs in the slice preparation
provide valuable support to mIPSC studies. Our studies showed that low-dose EtOH (1 and 5
mM) consistently enhanced VTA GABA neuron eIPSC amplitude (Fig. 8A, C; 1 mM;
F(1,13)=6.65, p=0.02 and 5 mM; F(1,15)=8.16, p=0.01). This effect was blocked by α-conotoxin MII
(α-CTX MII), indicating the involvement of α6*-nAChRs (Fig. 8B, D; 1 mM; F(1,11)=0.16,
p=0.691 and 5 mM; F(1,11)=0.07, p=0.796). However, results were inconsistent with higher doses
of EtOH, which also resulted in inconclusive results for the effects of α-CTX MII on eIPSCs in
the presence of EtOH. Furthermore, this EtOH effect is likely acting on GABA terminals, as the
paired-pulse ratio decreased, suggesting a presynaptic effect (Fig. 8).

Figure 8: Effects of EtOH and α-CTX MII, on eIPSCs in VTA GABA Neurons.
eIPSCs were recorded in VTA GABA neurons in the horizontal slice in the presence of APV/CNQX. EtOH
enhanced eIPSCs at low doses (A), but this effect was blocked in the presence of α-CTX MII (B). (C) Bar
graph summarizes the effects of EtOH (1 and 5 mM) and shows that α-CTX MII blocks this effect. Inset shows
EtOH enhancement in kynurenic acid + eticlopride, atropine and CGP55845.
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The Role of α6*-nAChRs in Acute Ethanol Actions on VTA DA Neurons
Acute EtOH’s Effect on VTA DA Neuron Firing Rate via α6*-nAChRs
The dogma is that local
circuit GABA neurons inhibit DA
neurons in the VTA. In order to link
the changes we found in VTA
GABA neurons to DA neurons, we
evaluated the effects of EtOH on
VTA DA neuron activity and DA
release in the NAc. In addition, we
examined the role α6*-nAChRs in
this process. Through recording DA
activity via firing rate we would be

Figure 9: Effects of EtOH and α-CTX MII on VTA DA Neuron
Firing Rate.
Using cell-attached mode, spontaneous spike activity was
measured in horizontal slices of GAD-GFP mice. Low doses of
EtOH inhibited DA activity while higher doses enhanced activity.
α-CTX MII was able to block EtOH’s low dose effects but not
with higher doses.

able to determine how EtOH may be acting on VTA GABA neurons to influence DA activity,
and ultimately release, a common trait of addiction. In our firing rate studies, we performed cellattached, voltage-clamped firing rate studies on VTA DA neurons in slice preparation from
GAD-GFP mice. VTA DA neurons were identified as non-glowing cells and through their
characteristically slow and regular firing rates. We found that low doses of EtOH (5 mM;
F(1,21)=12.58, p=0.002) inhibited VTA DA neuron activity, while high doses (50 mM;
F(1,15)=4.91, p=0.04 and 100 mM; F(1,7)=9.98, p=0.02) tended to increase activity (Fig. 9).
Furthermore, α-CTX MII was only able to block the effects of EtOH at the low dose level
(F(1,7)=0.70, p=0.43) , and did not appear to prevent the increase in firing rate associated with
higher doses of EtOH (50 mM; F(1,7)=6.39, p=0.04 and 100 mM; F(1,8)=5.84, p=0.04).
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Acute EtOH’s Effect on DA Release in the NAc via α6*-nAChRs
In efforts to expand our understanding concerning α6*-nAChRs in EtOH addiction, we
set to determine its role in DA release. In deciding which technique to employ, one concern arose
from the fact that microdialysis studies typically show a rise in DA levels while voltammetry
studies show a fall in evoked DA responses by both acute NIC and EtOH (Budygin, Phillips et al.
2001, Robinson, Howard et al. 2009, Zhang, Zhang et al. 2009, Yorgason, Ferris et al. 2013).
However, this disparity is largely due to the measurements of tonic versus phasic DA release
(Robinson, Howard et al. 2009). Recently it has been demonstrated that EtOH preferentially
inhibits high-frequency phasic release, but not low-frequency “tonic” release (Yorgason, Ferris et
al. 2013). Thus, we determined that fast-scan cyclic voltammetry (FSCV) was the best tool to
utilize.

Figure 10: EtOH Inhibits DA Release in the NAc.
(A) This graph shows the time course of 80 mM EtOH effects on a representative recording of DA release in
the NAc. (B) This graph shows an EtoH dose response on DA recordings. Increasing doses decreased DA
release. (C) This graph shows a frequency response on DA recordings (D) This graph summarizes the effects of
EtOH on DA. While MLA was without affect, the a6*-nAChR antagonist a-CTX-MII significantly attenuate
EtOH inhibition at 80 mM.
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As seen by others with FSCV, EtOH significantly decreased the peak amplitude of the
DA signal. We found that it had an IC50 of approximately 80 mM (Fig. 10A, B; 20 mM:
p=0.001, n=11; 40 mM: p=0.001, n=11; 80 mM: p=0.0002, n=11; 160 mM: p<0.0001, n=10).
EtOH significantly decreased the amplitude of the DA signal across all frequencies tested with
the exception of single pulse stimulation (Fig. 10C). Next, we wanted to measure the amount of
DA release in the presence of EtOH with the specific α7 and α6 nAChR antagonists
methylylcaconitine (MLA; 100 nM) and α-CTX MII [H9A; L15A] (500 nM), respectively. We
found that MLA did not alter EtOH inhibition of evoked DA release in the core at 80 mM EtOH
(Fig. 10D; F(1,20)=0.478, p=0.497). However, superfusion of the specific α6*-nAChR antagonist
α-CTX MII was able to significantly block EtOH’s inhibition of evoked DA release in the NAc
(Fig. 10D; F(1,30)=4.296, p=0.047).
The Role of α6*-nAChRs in Mediating Ethanol Consumption and Reward
Conditioned place preference (CPP) is a procedure used by many labs to study reward.
Given the changes in VTA GABA and DA neurons, including DA release in the NAc, that we
observed in our EtOH experimental
procedures, we attempted to use
CPP to show how these neuronal
alterations would manifest in
affecting behavior in mice. We
found that WT mice receiving
EtOH injections (2 g/kg IP)
showed a higher preference for the
EtOH compartment compared to

Figure 11: α6*-nAChR Mediate EtOH Consumption and Reward.
Results show WT mice have an EtOH preference, which is not
exhibited with α6 KO mice and mice treated with MEC, a
nonselective nAChR antagonist.
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EtOH treated α6 KO (Fig. 11). Furthermore, to ensure that α6 KO did not have any other
additional behavioral changes inherent to their genetic modification, we pretreated WT mice with
mecamylamine (MEC; 2 mg/kg), a non-α7 nAChR antagonist. The mice treated with MEC
showed similar preference to the α6 KO. A one way ANOVA demonstrated significance between
groups (F(2,26)=12.94, p=0.0002), with Bonferroni’s Multiple Comparison post-hoc analysis
demonstrating significance in C57 WT vs C57 WT + MEC (p<0.05) and C57 WT vs α6 KO
(p<0.05), with no difference in C57WT + MEC vs α6 KO.
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DISCUSSION
In recombinant SH-EP1 cells, NIC currents in functional α6*-nAChRs showed a
significant enhancement in the presence of EtOH. Our results confirmed the NIC and EtOH
interaction that others have previously observed through population-based samples and general
neuron activity in the VTA (Tizabi, Copeland et al. 2002, John, Meyer et al. 2003, Ford,
McCracken et al. 2012). While previous research revealed a synergistic relationship between
NIC and EtOH, we were able to outline that this mechanism of actions was likely working
through nAChRs, specifically α6*-nAChRs. We found that α6*-nAChRs showed a potent
response to low doses of NIC (1 μM) and EtOH (1 mM), which effect was blocked by α-CTX
P1A suggesting α6*-nAChRs probable direct involvement in mediating addiction in these two
drugs.
In order to increase our understanding of the role α6*-nAChRs in modulating alcoholism,
we needed to study native GABA neurons. We found that nicotine enhanced mIPSC frequency
in dissociated VTA GABA neurons. A change in mIPSC frequency suggests a presynaptic
response. As such, an increase in mIPSC frequency characterized greater inhibition to VTA
GABA neurons. This effect was blocked by α6*-nAChR antagonists, suggesting that nicotine
enhances inhibition to VTA GABA neurons via α6*-nAChRs to modulate addictive changes.
Low doses of EtOH (6 mM) also enhanced mIPSC frequency in dissociated VTA GABA
neurons. Administration of bicuculline helped determine that this inhibitory input is a result from
increased GABA release to VTA GABA neurons. Again, this increase in mIPSC frequency was
blocked by α6*-nAChR antagonists and not seen in α6 KO mice, suggesting that EtOH also
enhances GABA release on to VTA GABA neurons via α6*-nAChRs. These findings, mirroring
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NIC’s effects on mISPC, further support the hypothesis that NIC and EtOH, at physiologically
relevant levels, may be working through a shared mechanism.
Furthermore, an enhancement in mIPSC amplitude indicated that EtOH also had a
postsynaptic effect on VTA GABA neurons. EtOH could be acting directly on GABA(A)Rs in
addition to its presynaptic effect on GABA terminals via α6*-nAChRs to augment inhibition to
VTA GABA neurons. As with frequency, the increase in mIPSC amplitude was blocked by α6*nAChR antagonists and not observed in α6 KO mice too. Because α6*-nAChR antagonists
prevented the increase in mIPSCs, it is likely that this increased inhibition in VTA GABA
neurons is dependent on GABA release through α6*-nAChR. However, as a postsynaptic effect
exists, EtOH may have a dual role in enhancing GABA release and amplifying the subsequent
response.
Although EtOH increases inhibition to VTA GABA neurons, it was necessary to
determine if this increase was enough to alter VTA GABA neuron activity. Our results showed
that EtOH markedly lowered firing rate of dissociated VTA GABA neurons. Again, as seen with
our previous EtOH studies, this effect was blocked by α6*-nAChR antagonists. This
demonstrates that EtOH decreases VTA GABA activity via α6*-nAChRs, signifying the
potential role that α6*-nAChRs have in causing alcoholic addiction.
While our results supported a link between α6*-nAChRs and EtOH in the VTA in
dissociated neurons, it was pivotal to strengthen and prove the role that α6*-nAChR have with
EtOH in a more physiological setting. Using slice preparation as this resource, we found that low
doses of EtOH (1 and 5 mM) enhanced eIPSC amplitudes in VTA GABA neurons. Additionally,
this enhancement is blocked by α6*-nAChR antagonists, providing further support that
presynaptic α6*-nAChRs on GABA terminals modulate GABA release which is sensitive to

28

EtOH. This change in VTA GABA activity through α6*-nAChR could be the possible means by
which EtOH addiction is developed.
However, our DA experiments showed somewhat of a discrepancy. Similar to many
reports, we found that high doses of EtOH increased VTA DA firing rate (Brodie, Shefner et al.
1990). Moreover, we were also able to show that low doses of EtOH decreased VTA DA
activity. Alpha6*-nAChR antagonists were able to block the effects of low dose EtOH, but were
unable to do so in the higher doses. While there is evidence that α6*-nAChR may mediate
changes in VTA DA activity, it appears likely that α6*-nAChR may only be involved in lower
doses of EtOH.
While the effects of EtOH on GABA and DA may not coincide with what we expected to
see based on our theoretical model of the VTA network, there could be some other workings to
explain this discrepancy. It may be possible that the population of VTA GABA neurons we
studied do not inhibit DA neurons in the VTA. The inhibitory input to DA may be from areas
such as the RMTg or ventral pallidum, as there are GABA neurons from the RMTg that
innervate the VTA. Another possibility is that EtOH may have an independent effect on VTA
DA neurons. This may be plausible as high EtOH doses are unaffected by α6*-nAChR
antagonist. In addition, our FSCV studies of DA release in the NAc do not contain VTA GABA
neuron cell bodies. However, this is not very likely as α6*-nAChR antagonist block EtOH’s
effect on DA release, yet α6*-nAChR are not found on DA neurons. As we have hypothesized,
α6*-nAChR are likely to be located on GABA terminals, which are present in the NAc, where
they could synapse on DA terminals. As such, the VTA GABA neurons we studied might only
synapse with DA neurons at their terminals, therefore not having an effect on DA activity, but
only impacting DA release in the NAc. The latter theory is supported by our FSCV studies
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showing EtOH inhibition of dopamine release at terminals in the nucleus accumbens being
blocked by α6*-nAChR antagonists. Thus EtOH’s mechanism of action is likely to be through
α6*-nAChRs located on these VTA GABA terminals which synapse on DA terminals in the
NAc.
Lastly, CPP studies showed that WT mice tend to spend more time in the EtOH
compartment than α6 KO mice or mice treated with MEC, suggesting that α6*-nAChRs mediates
alcoholic behaviors in mice. This is vital, as it shows that α6*-nAChRs is involved in process of
addiction and its accompanying behaviors rather than the many physiological influences that
EtOH can have on the brain other than addiction, such as ataxia. As WT mice exhibited more
time in the EtOH compartment, it showed evidence that α6*-nAChRs are indeed involved in the
process of alcohol addiction. The behavioral differences demonstrate that α6*-nAChRs allow
EtOH to influence distinguishable reward-seeking behaviors caused by hijacking the mesolimbic
DA system.
Taken together, our results show that EtOH is acting through α6*-nAChRs on GABA
terminals to enhance GABA release. This enhancement of GABA release leads to greater
inhibition to VTA GABA neurons which has the potential to influence VTA DA neurons and
their release in the NAc. While further studies are necessary to outline the connection between
VTA GABA neurons and VTA DA neurons to completely understand the hodology involved in
EtOH addiction, our findings demonstrate a shared mechanism of alcohol and nicotine codependence. As this indicates some specificity in EtOH’s mode of action, we believe we have
identified a mechanism of alcohol addiction that could help facilitate the development of future
therapies/medications for the treatment of alcoholism and other addictions.
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